AR121438A1 - Composiciones farmacéuticas que comprenden acetato de 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il] e iones de sodio - Google Patents

Composiciones farmacéuticas que comprenden acetato de 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il] e iones de sodio

Info

Publication number
AR121438A1
AR121438A1 ARP210100496A ARP210100496A AR121438A1 AR 121438 A1 AR121438 A1 AR 121438A1 AR P210100496 A ARP210100496 A AR P210100496A AR P210100496 A ARP210100496 A AR P210100496A AR 121438 A1 AR121438 A1 AR 121438A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical compositions
quinazolin
piperazin
methoxyphenyl
trifluoromethyl
Prior art date
Application number
ARP210100496A
Other languages
English (en)
Inventor
Helmut Buschmann
Thomas Goldner
Jessica Redmer
Bertran Jordi Carles Ceron
Andrea Hawe
Matthias Lucke
Dorothea Hohmann
Monica Rosa
Original Assignee
Aic246 Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aic246 Gmbh & Co Kg filed Critical Aic246 Gmbh & Co Kg
Publication of AR121438A1 publication Critical patent/AR121438A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Abstract

La presente se refiere a nuevas composiciones farmacéuticas estables que contienen ácido 2-[(4S)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4H-quinazolin-4-il] acético e iones de sodio que están esencialmente libres de agentes solubilizantes formadores de complejos, tales como PEG, ciclodextrina, lisina, arginina, en particular HPBCD. La presente se refiere además a métodos de preparación de dichas composiciones farmacéuticas. La presente se refiere además al uso de dichas composiciones farmacéuticas en métodos de tratamiento y/o como profiláctico de enfermedades, particularmente su uso como un antivírico, preferentemente contra citomegalovirus.
ARP210100496A 2020-02-27 2021-02-26 Composiciones farmacéuticas que comprenden acetato de 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il] e iones de sodio AR121438A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP20159711 2020-02-27

Publications (1)

Publication Number Publication Date
AR121438A1 true AR121438A1 (es) 2022-06-08

Family

ID=69742713

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210100496A AR121438A1 (es) 2020-02-27 2021-02-26 Composiciones farmacéuticas que comprenden acetato de 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il] e iones de sodio

Country Status (19)

Country Link
US (1) US20230138444A1 (es)
EP (1) EP4110291A1 (es)
JP (1) JP2023520976A (es)
KR (1) KR20220148862A (es)
CN (1) CN115515565A (es)
AR (1) AR121438A1 (es)
AU (1) AU2021227276A1 (es)
BR (1) BR112022016868A2 (es)
CA (1) CA3169260A1 (es)
CL (1) CL2022002293A1 (es)
CO (1) CO2022012092A2 (es)
CU (1) CU20220051A7 (es)
EC (1) ECSP22066678A (es)
IL (1) IL295765A (es)
MX (1) MX2022010444A (es)
PE (1) PE20230514A1 (es)
TW (1) TW202140020A (es)
UY (1) UY39095A (es)
WO (1) WO2021170875A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR128035A1 (es) * 2021-12-21 2024-03-20 Aic246 Ag & Co Kg Composiciones farmacéuticas que comprenden acetato de 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il] e iones de potasio
CN114942278B (zh) * 2022-04-12 2023-09-08 山东诚创蓝海医药科技有限公司 来特莫韦中间体二d-(+)-二对甲基苯甲酰酒石酸乙酸乙酯络合物有关物质的分析方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10319612A1 (de) 2003-05-02 2004-11-18 Bayer Healthcare Ag Substituierte Dihydrochinazoline
DE102012101680A1 (de) 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Pharmazeutische Zubereitung enthaltend ein antiviral wirksames Dihydrochinazolinderivat
DE102012101659A1 (de) 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Salze eines Dihydrochinazolinderivats
WO2014047562A2 (en) * 2012-09-21 2014-03-27 Epiphany Biosciences Method of treating and/or preventing shingles and method of treating and/or preventing zoster associated pain
CN109966244A (zh) * 2017-12-27 2019-07-05 天津耀辰实业发展有限公司 一种含有乐特莫韦的药物组合物

Also Published As

Publication number Publication date
TW202140020A (zh) 2021-11-01
ECSP22066678A (es) 2022-12-30
CU20220051A7 (es) 2023-04-10
CO2022012092A2 (es) 2022-11-08
EP4110291A1 (en) 2023-01-04
MX2022010444A (es) 2022-10-18
US20230138444A1 (en) 2023-05-04
CA3169260A1 (en) 2021-09-02
PE20230514A1 (es) 2023-03-24
IL295765A (en) 2022-10-01
UY39095A (es) 2021-09-30
KR20220148862A (ko) 2022-11-07
AU2021227276A1 (en) 2022-10-20
WO2021170875A1 (en) 2021-09-02
CL2022002293A1 (es) 2023-02-03
CN115515565A (zh) 2022-12-23
JP2023520976A (ja) 2023-05-23
BR112022016868A2 (pt) 2023-02-28

Similar Documents

Publication Publication Date Title
CO2022012092A2 (es) Composiciones farmacéuticas que comprenden acetato de 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il] e iones de sodio.
HRP20201268T1 (hr) Stabilne formulacije koje sadrže anti-pcsk9 antitijela
CY1122181T1 (el) Φαρμακοτεχνικη μορφη αντισωματος
AR109461A2 (es) Formulación de anticuerpo anti-cd20 y su uso para preparar un medicamento
CY1124690T1 (el) Σκευασματα ενδοφλεβιου διαλυματος ποσακοναζολης σταθεροποιημενα με υποκατεστημενη βητα-κυκλοδεξτρινη
CY1124910T1 (el) Μεθοδοι και συνθεσεις για παραδοση στο κνς της αρυλοσουλφατασης α
MA33723B1 (fr) Excipient stabilisant pour vaccin a virus entiers inactives
MX2016008156A (es) Formar fibras de queratina con el uso de un agente activo que comprende un grupo funcional seleccionado del grupo que consiste en: -c(=o)-, -c(=o)-h y -c(=o)-o-.
EA031209B9 (ru) Фармацевтический состав антитела для лечения воспалительного заболевания и способы его применения
CL2012000821A1 (es) Composicion inmunogenica de reovirus de peces (prv) que comprende acido nucleico del prv; uso de la composicion inmunogenica que sirve para preparar un medicamento util para tratar afecciones de infeccion por prv en un animal.
ECSP088159A (es) Formulaciones de inmunoconjugado
TR200401029T4 (tr) Asilfenil-üre türevleri, imalat yöntemleri ve ilaç maddesi olarak kullanımları
ES2721148T3 (es) Composiciones farmacéuticas de paclitaxel, análogos de paclitaxel o conjugados de paclitaxel y métodos relacionados de preparación y uso
ES2722201T3 (es) Composiciones y procedimientos útiles para estabilizar formulaciones que contienen proteínas
EA201390826A1 (ru) ПИРИМИДИНОНОВЫЕ СОЕДИНЕНИЯ ДЛЯ ПРИМЕНЕНИЯ В ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ ИЛИ СОСТОЯНИЙ, ОПОСРЕДОВАННЫХ Lp-PLA
NZ628444A (en) Pharmaceutical preparation containing an antivirally active dihydroquinazoline derivative
AR074541A1 (es) Composiciones desinfectantes de plata naturales
ECSP22066676A (es) 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5- (trifluorometil)fenil]-4h-quinazolin-4-il] acetato de sodio y composiciones farmacéuticas del mismo
CR20140053A (es) Formulaciones de ácido desoxicólico y sales del mismo
BRPI0915513B8 (pt) compostos derivados de ácido fenóxi-cromano carboxílico 6-substituído, composições farmacêuticas compreendendo os referidos compostos, uso dos mesmos, e processo para a preparação destes
EA200801411A1 (ru) Новые адъюванты на основе конъюгатов и производных бис-ацилоксипропилцистеина и их применения в фармацевтических композициях
MA35158B1 (fr) Formulations topiques de type suspension comprenant un depsipeptide cyclique
Boey et al. Cerium oxide nanoparticles alleviate hepatic fibrosis phenotypes in vitro
PE20100471A1 (es) Composicion de liberacion pulsatil de sildenafil y proceso para prepararla
TR201901792T4 (tr) Yeni (trimetoksifenilamino)pirimidinil formülasyonları.